US regulatory status: approved.
pharma · Alzheimer Disease · Pulmonary Fibrosis
Shanghai University of
Shanghai University of Traditional Chinese Medicine
Shanghai University of drug portfolio — 33 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Shanghai, China, CN HQ
6 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Shanghai, China, CN
- Employees
- 6
- Programs
- 24
- Drugs
- 33
- Patents
- 0
Shanghai University of pipeline
Portfolio lens on 33 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Shanghai University of drug portfolio — 33 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Shanghai University of in public FDA and regional records.
-
Development asset linked to Shanghai University of in public FDA and regional records.
-
Development asset linked to Shanghai University of in public FDA and regional records.
-
Development asset linked to Shanghai University of in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Shanghai University of in public FDA and regional records.
-
Development asset linked to Shanghai University of in public FDA and regional records.
-
Development asset linked to Shanghai University of in public FDA and regional records.
-
Development asset linked to Shanghai University of in public FDA and regional records.
-
Development asset linked to Shanghai University of in public FDA and regional records. Mechanism: Acetylcholinesterase inhibitor.
- Mechanism
- Acetylcholinesterase inhibitor
-
Development asset linked to Shanghai University of in public FDA and regional records. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
Development asset linked to Shanghai University of in public FDA and regional records.
-
Development asset linked to Shanghai University of in public FDA and regional records.
-
Development asset linked to Shanghai University of in public FDA and regional records.
-
Development asset linked to Shanghai University of in public FDA and regional records. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 antagonist
-
Development asset linked to Shanghai University of in public FDA and regional records.
-
Development asset linked to Shanghai University of in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to Shanghai University of in public FDA and regional records.
-
Development asset linked to Shanghai University of in public FDA and regional records.
-
Development asset linked to Shanghai University of in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Shanghai University of in public FDA and regional records.
-
Development asset linked to Shanghai University of in public FDA and regional records.
-
Development asset linked to Shanghai University of in public FDA and regional records.
-
Development asset linked to Shanghai University of in public FDA and regional records.
-
Development asset linked to Shanghai University of in public FDA and regional records.
-
Development asset linked to Shanghai University of in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Shanghai University of in public FDA and regional records.
-
Development asset linked to Shanghai University of in public FDA and regional records.